Yujie Zhao, M.D., Ph.D.

  1. Internist
  2. Oncologist
  1. Rao S, Li S, Connor D, Fournier L, Manochakian R, Lou Y, Zhao Y. Disease monitoring using plasma-based circulating tumor DNA (ctDNA) assays in rare malignancies. J Clin Oncol. 2024; 42(suppl 16; abstr e15046).
  2. Crompton DJ, Mohammadi H, Pirgousis P, Patel S, Janus J, Zhao Y, McGee LA, Patel SH, Routman DM, Ma DJ, Holtzman AL. Elective Irradiation of Retropharyngeal Lymph Nodes as an Indication for Adjuvant Radiation Therapy After Transoral Surgery for Tonsil Cancer. Pract Radiat Oncol. 2024 May 13 [Epub ahead of print]
    View PubMed
  3. Li S, Manochakian R, Chen R, Patel J, Inampudi JV, Hiren KR, Zhao Y, Lou Y. Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy. Front Oncol. 2024; 14:1306311 Epub 2024 Feb 07
    View PubMed
  4. Sacchi de Camargo Correia G, Zhao Y, Manochakian R, Lou Y. The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer. Front Oncol. 2024; 14:1336546 Epub 2024 Feb 27
    View PubMed
  5. McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis. Front Oncol. 2024; 14:1417175 Epub 2024 June 21
    View PubMed
  6. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  7. Majeed U, Seegobin K, Lewis J, Li S, Zhao Y, Lou Y, Manochakian R. Lung Cancer in Patients With Lynch Syndrome: Association or Coincidence? Clin Lung Cancer. 2023 Nov; 24 (7):e237-e241 Epub 2023 May 31
    View PubMed
  8. Sacchi de Camargo Correia G, Pai T, Li S, Connor D, Zhao Y, Lou Y, Manochakian R. Immune-Related Adverse Events in Patients with Lung Cancer. Curr Oncol Rep. 2023 Nov; 25 (11):1259-1275 Epub 2023 Oct 02
    View PubMed
  9. Majeed U, Li S, Seegobin K, Nassar A, Manochakian R, Zhao Y, Lou Y. First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report. JTO Clin Res Rep. 2023 Jul; 4 (7):100536 Epub 2023 June 15
    View PubMed
  10. Seegobin K, Nassar A, Manochakian R, Zhao Y, Lou Y. First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient with ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma with a Novel Combination of Temozolomide and Lorlatinib: A Case Report JTO Clinical and Research Reports. 2023.
  11. Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers (Basel). 2023 May 24; 15(11).
    View PubMed
  12. Tun AJ, Hoppe BS, Zhao Y, Makey I, Fernandez-Bussy S, Liang X. Radiation Therapy for Primary Adenoid Cystic Carcinoma of the Trachea: Photons, Protons, or Carbon. Int J Part Ther. 2023 Spring; 9 (4):302-305 Epub 2023 Jan 12
    View PubMed
  13. Butts E, Gococo-Benore D, Pai T, Moustafa MA, Heng F, Chen R, Zhao Y, Manochakian R, Lou Y. Brief report: risk stratification following curative therapy for stage I NSCLC. Front Oncol. 2023; 13:1250315. Epub 2023 Aug 14.
    View PubMed
  14. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
  15. Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y, Lou Y. Genomic landscape of lung adenocarcinomas in different races. Front Oncol. 2022; 12:946625 Epub 2022 Sept 28
    View PubMed
  16. Sh Ahmed O, Mahadevia H, Manochakian R, Zhao Y, Salinas M, Khoor A, LeGout J, Lou Y. A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab. Case Rep Oncol. 2022 Sep-Dec; 15(3):1063-1073. Epub 2022 Nov 28.
    View PubMed
  17. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021 Jul 8; 14 (1):108 Epub 2021 July 08
    View PubMed
  18. Wiest NE, Tzou KS, Olson MT, Herchko SM, Bajalia EM, Thiel DD, Lou Y, Zhao Y, Manochakian R. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature. Clin Case Rep. 2021 Jun; 9 (6):e04278 Epub 2021 June 10
    View PubMed
  19. Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021 May 12; 14 (1):78
    View PubMed
  20. He S, Lian C, Thorstad W, Gay H, Zhao Y, Ruan S, Wang X, Li H. A novel systematic approach for cancer treatment prognosis and its applications in oropharyngeal cancer with microRNA biomarkers. Bioinformatics. 2021 Apr 29 [Epub ahead of print]
    View PubMed
  21. Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R, Zhao Y, Ailawadhi S, Lou Y. Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Netw Open. 2021 Jan 4; 4 (1):e2032276 Epub 2021 Jan 04
    View PubMed
  22. Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:751209 Epub 2021 Nov 16
    View PubMed
  23. Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol. 2021; 11:750657 Epub 2021 Dec 01
    View PubMed
  24. Shi H, Zhou K, Cochuyt J, Hodge D, Qin H, Manochakian R, Zhao Y, Ailawadhi S, Adjei AA, Lou Y. Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Front Oncol. 2021; 11:773958 Epub 2021 Dec 10
    View PubMed
  25. Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020 May 24; 13 (1):58
    View PubMed
  26. Seegobin K, Majeed U, Lou Y, Zhao Y, Manochakian R. Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature. SAGE Open Med Case Rep. 2020; 8:2050313X20966895. Epub 2020 Oct 24.
    View PubMed
  27. Mitsis D, Opyrchal M, Zhao Y, Kane Iii JM, Cheney R, Salerno KE. Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient with Metastatic Sarcoma. Cureus. 2015 Dec 28; 7 (12):e439
    View PubMed
  28. Ngamphaiboon N, Dy GK, Ma W, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33: (1)225-32.
    View PubMed
  29. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10 (1):172-80
    View PubMed
  30. Gandhi S, Chen H, Zhao Y, Dy GK. First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl). 2015; 6:71-82 Epub 2015 Sept 18
    View PubMed
  31. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014 Jul; 11: (7)385-400.
    View PubMed
  32. Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks WL Jr, Rigual NR, Sullivan MA, Seshadri M, Marshall JR, Cohan DM, Zhao Y, Singh AK. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck. 2014 May; 36 (5):694-701 Epub 2013 Oct 07
    View PubMed
  33. Sehdev A, Zhao Y, Singh AK, Sharma N. Primary small cell carcinoma of the tonsil: a case report and review of the literature. Case Rep Oncol. 2012 Sep; 5 (3):537-41 Epub 2012 Oct 05
    View PubMed
  34. Zhao Y, Ramakrishnan A, Kim KE, Rabson AB. Regulation of Bcl-3 through interaction with the Lck tyrosine kinase. Biochem Biophys Res Commun. 2005 Sep 30; 335 (3):865-73
    View PubMed